The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: A population-based analysis from the health surveys for England 1991-94

Diabetic Medicine

Volumn 16, Issue 1, 1999, Pages 35-40

  Colhoun, Helen M ^a,d   Dong, W ^a   Barakat, M T ^b   Mather, H M ^b   Poulter, N R ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b EALING HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular risk; Diabetes; England; Guidelines; Lipid lowering

Indexed keywords

CHOLESTEROL;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; HYPERTENSION; OBESITY; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING; UNITED KINGDOM;

EID: 0033051401     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00017.x     Document Type: Article

References (19)

1. 1 Krans HMJ, Porta M, Keen H (eds). Diabetes Care and Research in Europe: the St Vincent Declaration Action Programme. Copenhagen: WHO Regional Office for Europe, International Diabetes Federation European Region, 1992.
2. 2 Colhoun HM, Prescott-Clarke P. Health Survey for England 1994. London: HMSO, 1996.
3. 3 Bennett N, Dodd T, Flateley J, Freeth S, Bolling K. Health Survey for England 1993. London: HMSO 1995.
4. 4 Standing Medical Advisory Committee. The Use of Statins. London: Department of Health 1997.
5. 5 Ramsay LE, Haq IU, Jackson PR, Yeo WW. The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet 1996; 348: 1251-1252.
6. 6 Jones AF. Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines. Lancet 1997; 350: 1174-1175.
7. 7 UK Prospective Diabetes Study Group UK, Prospective Diabetes Study (UKPDS). XI. Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabetic Med 1994; 11: 534-544.
8. 8 European IDDM, Policy Group. Consensus Guidelines for the Managaement of Insulin-Dependent (Type I) Diabetes. Diabetic Med 1993; 10: 990-1005.
9. 9 Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
10. 10 Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci Colch 1996; 91: 399-413.
11. 11 Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979; 2: 120-126.
12. 12 Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59: 8-13.
13. 13 Abbott RD, Donahue RP, Kannel WB, Wilson PWF. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988; 260: 3456-3460.
14. 14 Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ. Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO multinational study of vascular disease in diabetics. Diabetologia 1991; 34: 584-589.
15. 15 Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications. Diabetes Care 1992; 15: 1141-1155.
16. 16 Haq IU, Jackson PR, Yeo WW, Ramsay LE. A comparison of methods for targeting CHD risk for primary prevention. Heart 1997; 77 (Suppl 1): 38.
17. 17 Haffner SM. The Scandinavian Simavastatin Survival Study (4S) Subgroup Analysis of Diabetic Subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997; 20: 469-471.
18. 18 American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: S36-S39.
19. 19 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.